Medullary Thyroid Cancer

Adults with medullary thyroid cancer who develop osteolytic bone metastases are more likely to experience skeletal-related adverse events compared with similar patients who develop osteoblastic bone metastases, suggesting that antiresorptive therapies should be considered based on the morphology of disease, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

The investigational therapy pralsetinib appeared effective and safe for patients with RET fusion-positive non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

CHICAGO — Investigators from The Ohio State University Comprehensive Cancer Center have initiated research on the proteomic gene alterations in medullary thyroid cancer to develop better targeted therapies for this patient population, according to data presented at the Annual Meeting of the American Thyroid Association.

INDIAN WELLS, Calif. — Medullary thyroid cancer is a complex disease that presents unique challenges, speakers said here. Careful consideration of its molecular components and insight into management issues, however, can help clinicians overcome these hurdles.

In this video, Megan Haymart, MD, Professor of Medicine at the University of Michigan School of Medicine, discusses the relative lack of known risk factors for thyroid cancer, including family history and radiation exposure.